摘要
目的探讨两种抗血管生成药(重组人血管内皮抑制素恩度和沙利度胺)联合卡培他滨和奥沙利铂(XELOX)方案治疗晚期结直肠癌的疗效及安全性.方法选取2015年1月到2018年5月合肥市第一人民医院及安徽省立医院收治的伴有脏器转移灶、不可手术切除的晚期结直肠癌患者40例,将其随机分为试验组和对照组,每组均为20例.试验组静脉泵入恩度(第1~7天)同时口服沙利度胺(第1~14天)联合XELOX化疗(第6~19天).对照组采用XELOX化疗方案(第6~19天).结果试验组和对照组患者的客观缓解率(objective responserate,ORR)分别为50%(10/20)和20%(4/20)(χ^2=3.956,P=0.047),疾病控制率(disease control rate,DCR)分别为85%(17/20)和70%(14/20)(χ^2=1.290,P=0.256),两组患者的中位无进展生存期(median progression free survival, mPFS)分别为6.8个月和5.3个月,差异有统计学意义(P<0.05),两组患者治疗前后卡氏功能状态评分(Karnofsky performance score,KPS)及不良反应发生率比较差异无统计学意义(P>0.05).结论恩度加沙利度胺联合XELOX化疗一线治疗晚期转移性结直肠癌有较好的疗效及安全性.
Objective To investigate the efficacy and safety of two antiangiogenic drugs (recombinant human endostatin endostar and thalidomide)combined with capecitabine and oxaliplatin(XELOX)regimens in the treatment of advanced colorectal cancer. Methods From January 2015 to May 2018, 40 patients of advanced metastatic colorectal cancer with organ metastasis and non-resectable were selected from the first people′s hospital of Hefei and Anhui Provincial Hospital, and they were randomly divided into treatment and control group, with 20 cases in each group.The treatment group received intravenous infusion (IV)of endostar for continuous 7 days (day 1~7)combined with oral administration of thalidomide for continuous 14 days (day 1~14)plus XELOX regimens after the fifth dose of endostar (day 6~19), and the control group was treated with XELOX regimen (day6~19). Results The objective response rate (ORR)was 50%(10/20)and 20%(4/20)respectively (χ^2=3.956, P<0.05), the disease control rate (DCR)was 85%(17/20)and 70%(14/20)respectively (χ^2=1.290, P>0.05), and the median progression free survival (mPFS)was 6.8 in both groups.There was no significant difference in Karnofsky performance score (KPS)and incidence of adverse reactions between the two groups before and after treatment (P>0.05). Conclusion Combination of endostar and thalidamide plus XELOX regimen as first-line treatment have better antitumor activity and are well-tolerated in patients with advanced colorectal cancer.
作者
李玉芝
鲍扬漪
孙峰
朱婷
Li Yuzhi;Bao Yangyi;Sun Feng;Zhu Ting(Department of hematology and oncology, the third affiliated hospital of Anhui Medical University & the first people′s hospital of Hefei, hefei 230061, China)
出处
《中国综合临床》
2019年第5期435-439,共5页
Clinical Medicine of China
基金
合肥市借转补医疗卫生项目(YW201512010003).
